by TractManager | Jul 24, 2019 | Health Technology Assessment
Health Problem: Chronic pain, or pain persisting > 6 months, is a multifaceted condition with an estimated prevalence of 2% to 40% in adults in the United States. There are numerous etiologies of chronic noncancer pain. Treatment of chronic pain depends on individual...
by TractManager | Jul 22, 2019 | Emerging Technology Report
Brineura is recombinant human tripeptidyl peptidase 1 (TPP1) replacement enzyme to slow loss of walking ability in symptomatic pediatric patients aged 3 years and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2). Brineura is infused into the...
by TractManager | Jul 22, 2019 | Emerging Technology Report
Brineura is recombinant human tripeptidyl peptidase 1 (TPP1) replacement enzyme to slow loss of walking ability in symptomatic pediatric patients aged 3 years and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2). Brineura is infused into the...
by TractManager | Jul 19, 2019 | Health Technology Assessment
Health Problem: Systemic sclerosis (SSc) is a progressively disabling autoimmune disease of the connective tissue that causes skin thickening; the disease can thicken visceral connective tissue that results in organ impairment, organ failure, and mortality. SSc is a...
by TractManager | Jul 18, 2019 | Emerging Technology Report
Onpattro (patisiran) is an intravenous RNA interference (RNAi) therapeutic agent for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. RNAi is a natural cellular process of gene silencing. Onpattro is designed to silence...
Recent Comments